The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Open accessAbstract
Schizophrenia has been primarily associated with dopamine dysfunction, and treatments have been developed that target the dopamine pathway in the central nervous system. However, accumulating evidence has shown that the core pathophysiology of schizophrenia might involve dysfunction in dopaminergic, glutamatergic, serotonergic, and gamma-aminobutyric acid (GABA) signaling, which may lead to aberrant functioning of interneurons that manifest as cognitive, behavioral, and social dysfunction through altered functioning of a broad range of macro- and microcircuits. The interactions between neurotransmitters can be modeled as nodes and edges by using graph theory, and oxidative balance, immune, and glutamatergic systems may represent multiple nodes interlocking at a central hub; imbalance within any of these nodes might affect the entire system. Therefore, this review attempts to address novel treatment targets beyond the dopamine hypothesis, including glutamate, serotonin, acetylcholine, GABA, and inflammatory cytokines. Furthermore, we outline that these treatment targets can be possibly integrated with novel treatment strategies aimed at different symptoms or phases of the illness. We anticipate that reversing anomalous activity in these novel treatment targets or combinations between these strategies might be beneficial in the treatment of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Driving fast-spiking cells induces gamma rhythm and controls sensory responses
Cardin, J. A., Carlén, M., Meletis, K., Knoblich, U., Zhang, F., Deisseroth, K., Tsai, L.-H., & Moore, C. I. (2009) · Nature · doi:10.1038/nature08002 · Cited by 2,603
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Abnormal neural oscillations and synchrony in schizophrenia
Uhlhaas, P. J., & Singer, W. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2774 · Cited by 2,120
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia
Fletcher, P. C., & Frith, C. D. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2536 · Cited by 1,462
The NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease
Stephan, A. H., Barres, B. A., & Stevens, B. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113810 · Cited by 1,113
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., & Ballard, C. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Definition and description of schizophrenia in the DSM-5
Tandon, R., Gaebel, W., Barch, D. M., Bustillo, J., Gur, R. E., Heckers, S., Malaspina, D., Owen, M. J., Schultz, S., Tsuang, M., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.028 · Cited by 807
Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder
Green, M. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.1006e12 · Cited by 801
From prediction error to incentive salience: mesolimbic computation of reward motivation.
Berridge, K. C. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.07990.x · Cited by 700
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmüller, B. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90178-0 · Cited by 694
Kim, Y.-K., Na, K.-S., Myint, A.-M., & Leonard, B. E. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.008 · Cited by 620
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars
Benes, F. M., Lim, B., Matzilevich, D., Walsh, J. P., Subburaju, S., & Minns, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703806104 · Cited by 483
Nicotinic ACh receptors as therapeutic targets in CNS disorders
Dineley, K. T., Pandya, A. A., & Yakel, J. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.002 · Cited by 450
The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia
Na, K.-S., Jung, H.-Y., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.022 · Cited by 427
Bringing Order to the Glutamate Chaos in Schizophrenia
Moghaddam, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00757-8 · Cited by 403
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Schizophrenia, “just the facts”: What we know in 2008Part 3: Neurobiology
KESHAVAN, M., TANDON, R., BOUTROS, N., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.020 · Cited by 347
Use of Epigenetic Drugs in Disease: An Overview
Heerboth, S., Lapinska, K., Snyder, N., Leary, M., Rollinson, S., & Sarkar, S. (2014) · Genetics & Epigenetics · doi:10.4137/geg.s12270 · Cited by 326
Pathophysiologically based treatment interventions in schizophrenia
Lewis, D. A., & Gonzalez-Burgos, G. (2006) · Nature Medicine · doi:10.1038/nm1478 · Cited by 323
Cannabis and psychosis/schizophrenia: human studies
D’Souza, D. C., Sewell, R. A., & Ranganathan, M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0024-2 · Cited by 295
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
Genetic Risk for Schizophrenia: Convergence on Synaptic Pathways Involved in Plasticity
Hall, J., Trent, S., Thomas, K. L., O’Donovan, M. C., & Owen, M. J. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.07.011 · Cited by 290
Inflammation and the two-hit hypothesis of schizophrenia
Feigenson, K. A., Kusnecov, A. W., & Silverstein, S. M. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.006 · Cited by 282
Chaudhry, I. B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S., Dunn, G., & Deakin, B. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444941 · Cited by 279
Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262
Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256
Egerton, A., Chaddock, C. A., Winton-Brown, T. T., Bloomfield, M. A. P., Bhattacharyya, S., Allen, P., McGuire, P. K., & Howes, O. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.017 · Cited by 253
Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Möller, H.-J., Klauss, V., Schwarz, M. J., & Riedel, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.015 · Cited by 250
GABA and Schizophrenia: A Review of Basic Science and Clinical Studies
Wassef, A., Baker, J., & Kochan, L. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095349.32154.a5 · Cited by 244
Umbricht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E. A., Ostland, M., Wallace, T. L., Knoflach, F., Dorflinger, E., Wettstein, J. G., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.163 · Cited by 234
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Jones, C. K., Byun, N., & Bubser, M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.199 · Cited by 225
Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222
Anti-NMDA receptor encephalitis, autoimmunity, and psychosis
Kayser, M. S., & Dalmau, J. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.007 · Cited by 220
Epigenetic GABAergic targets in schizophrenia and bipolar disorder
Guidotti, A., Auta, J., Chen, Y., Davis, J. M., Dong, E., Gavin, D. P., Grayson, D. R., Matrisciano, F., Pinna, G., Satta, R., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.021 · Cited by 218
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy
Bernstein, H.-G., Steiner, J., Guest, P. C., Dobrowolny, H., & Bogerts, B. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.035 · Cited by 203
Howes, O. D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P. K., & Turkheimer, F. (2013) · Brain · doi:10.1093/brain/awt264 · Cited by 198 · cited 1×
“In early imaging studies based on positron emission tomography (PET), patients with schizophrenia showed increased dopamine activity in the striatum [5] and the midbrain origin of neurons [6] compared with the controls.”
BackgroundThe NMDA Receptor Hypofunction Model of Psychosis
FARBER, N. B. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.008 · Cited by 190
Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia
Moghaddam, B. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1792-z · Cited by 189
Attenuated psychosis syndrome in DSM-5
Tsuang, M. T., Van Os, J., Tandon, R., Barch, D. M., Bustillo, J., Gaebel, W., Gur, R. E., Heckers, S., Malaspina, D., Owen, M. J., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.004 · Cited by 182
α7-Nicotinic Acetylcholine Receptor Agonists for Cognitive Enhancement in Schizophrenia
Freedman, R. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092112-142937 · Cited by 174
Kenk, M., Selvanathan, T., Rao, N., Suridjan, I., Rusjan, P., Remington, G., Meyer, J. H., Wilson, A. A., Houle, S., & Mizrahi, R. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu157 · Cited by 169
Marx, C. E., Bradford, D. W., Hamer, R. M., Naylor, J. C., Allen, T. B., Lieberman, J. A., Strauss, J. L., & Kilts, J. D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.076 · Cited by 160
Epigenetic mechanisms of importance for drug treatment
Ivanov, M., Barragan, I., & Ingelman-Sundberg, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.05.004 · Cited by 159
Paulman, R. G., Devous, M. D., Gregory, R. R., Herman, J. H., Jennings, L. W., Bonte, F. J., Nasrallah, H. A., & Raese, J. D. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90549-h · Cited by 154
The genetics of sensory gating deficits in schizophrenia
Freedman, R., Olincy, A., Ross, R. G., Waldo, M. C., Stevens, K. E., Adler, L. E., & Leonard, S. (2003) · Current Psychiatry Reports · doi:10.1007/s11920-003-0032-2 · Cited by 153
The Complement System in Schizophrenia
Mayilyan, K. R., Weinberger, D. R., & Sim, R. B. (2008) · Drug News & Perspectives · doi:10.1358/dnp.2008.21.4.1213349 · Cited by 153
Stauffer, V. L., Millen, B. A., Andersen, S. W., Kinon, B. J., LaGrandeur, L., Lindenmayer, J., & Gomez, J. C. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.020 · Cited by 140
New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy
Urs, N. M., Peterson, S. M., & Caron, M. G. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.10.011 · Cited by 137
Neurotensin: Role in psychiatric and neurological diseases
Cáceda, R., Kinkead, B. L., & Nemeroff, C. B. (2006) · Peptides · doi:10.1016/j.peptides.2006.04.024 · Cited by 136
Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men
D, A. O. M., & Stevens, K. E. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.015 · Cited by 135
Nicotine Withdrawal and Psychiatric Symptoms in Cigarette Smokers with Schizophrenia
Dalack, G. W., Becks, L., Hill, E., Pomerleau, O. F., & Meador-Woodruff, J. H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00121-3 · Cited by 133
Brunzell, D. H., & McIntosh, J. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.299 · Cited by 132
Alberati, D., Moreau, J., Lengyel, J., Hauser, N., Mory, R., Borroni, E., Pinard, E., Knoflach, F., Schlotterbeck, G., Hainzl, D., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.008 · Cited by 128
Modabbernia, A., Rezaei, F., Salehi, B., Jafarinia, M., Ashrafi, M., Tabrizi, M. H., Hosseini, S. M. R., Tajdini, M., Ghaleiha, A., & Akhondzadeh, S. (2012) · CNS Drugs · doi:10.1007/s40263-012-0022-1 · Cited by 124
Cholinergic aspects of schizophrenia
Tandon, R. (1999) · The British Journal of Psychiatry · doi:10.1192/s0007125000293586 · Cited by 121
Padmanabhan, J. L., Tandon, N., Haller, C. S., Mathew, I. T., Eack, S. M., Clementz, B. A., Pearlson, G. D., Sweeney, J. A., Tamminga, C. A., & Keshavan, M. S. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu075 · Cited by 121
Alterations of Serotonin Transmission in Schizophrenia
Abi‐Dargham, A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78005-9 · Cited by 120
Schizophrenia and the Motivation for Smoking
Forchuk, C., Norman, R. M. G., MALLA, A. K., Martin, M., McLean, T. S., Cheng, S. K. K., Diaz, K. M., McIntosh, E., Rickwood, A., Vos, S. H., et al. (2009) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2002.tb00656.x · Cited by 117
A Dopamine D2 Receptor-DISC1 Protein Complex may Contribute to Antipsychotic-Like Effects
Su, P., Li, S., Chen, S., Lipina, T. V., Wang, M., Lai, T. K. Y., Lee, F. H. F., Zhang, H., Zhai, D., Ferguson, S. S. G., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.11.007 · Cited by 115
Putative neuroprotective agents in neuropsychiatric disorders
Dodd, S., Maes, M. H. J., Anderson, G., Dean, O. M., Moylan, S., & Berk, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.007 · Cited by 114
Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia
Usall, J., Huerta‐Ramos, E., Iniesta, R., Cobo, J., Araya, S., Roca, M., Serrano‐Blanco, A., Teba, F., & Ochoa, S. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06610 · Cited by 108
Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?
Arranz, M. J., & Kapur, S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn114 · Cited by 107
Mcloughlin, B. C., Pushpa-Rajah, J. A., Gillies, D. M., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004837.pub3 · Cited by 98
Schizophrenia as a Disorder of Molecular Pathways
Horváth, S., & Mirnics, K. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.01.001 · Cited by 96
The Interaction Between GABA and Dopamine: Implications for Schizophrenia
Garbutt, J. C., & van Kammen, D. P. (1983) · Schizophrenia Bulletin · doi:10.1093/schbul/9.3.336 · Cited by 94
de Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
Pharmacogenetics in psychiatry: translating research into clinical practice
Ak, M., Zhang, J.-P., & Lencz, T. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.146 · Cited by 88
Losing Control Under Ketamine: Suppressed Cortico-Hippocampal Drive Following Acute Ketamine in Rats
Moran, R., Jones, M. W., Blockeel, A. J., Adams, R. A., Stephan, K. E., & Friston, K. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.184 · Cited by 83
Satow, A., Maehara, S., Ise, S., Hikichi, H., Fukushima, M., Suzuki, G., Kimura, T., Tanak, T., Ito, S., Kawamoto, H., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138107 · Cited by 73
Dencker, D., Thomsen, M., Wörtwein, G., Weikop, P., Cui, Y., Jeon, J., Wess, J., & Fink‐Jensen, A. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200110q · Cited by 68
Effect of anticholinergics on positive and negative symptoms in schizophrenia.
Tandon, R., DeQuardo, J. R., Goodson, J. A., Mann, N. A., & Greden, J. F. (1992) · PubMed · Cited by 65
The Role of α5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia
Gill, K. M., & Grace, A. A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131216114612 · Cited by 65
Brain-specific epigenetic markers of schizophrenia
Wockner, L. F., Morris, C. P., Noble, E. P., Lawford, B. R., Whitehall, V., Young, R. M., & Voisey, J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.177 · Cited by 64
Psychopharmacology of the negative symptoms: Current status and prospects for progress
Davis, M. C., Horan, W. P., & Marder, S. R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.010 · Cited by 63
Dunlop, J., & Brandon, N. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565806 · Cited by 63
Jackson, J. R., Eaton, W. W., Cascella, N. G., Fasano, A., Warfel, D. T., Feldman, S. M., Richardson, C., Vyas, G. R., Linthicum, J., Santora, D., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.011 · Cited by 61
Liu, W., Downing, A. C., Munsie, L. M., Chen, P., Reed, M. R., Ruble, C., Landschulz, K. T., Kinon, B. J., & Nisenbaum, L. K. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.90 · Cited by 57
The Cholinergic System: An Emerging Drug Target for Schizophrenia
Gibbons, A. S., & Dean, B. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160127114010 · Cited by 57
Iasevoli, F., Tomasetti, C., Buonaguro, E. F., & de Bartolomeis, A. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140324183406 · Cited by 56
Schizophrenia biomarkers: Translating the descriptive into the diagnostic
Pickard, B. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114566631 · Cited by 54
The GABA System in Schizophrenia: Cells, Molecules and Microcircuitry
Benes, F. M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.017 · Cited by 52
Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study
Edwards, A. C., Bacanu, S., Bigdeli, T. B., Moscati, A., & Kendler, K. S. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.06.016 · Cited by 48
Potential serotonergic agents for the treatment of schizophrenia
Garay, R. P., Bourin, M., de Paillette, E., Samalin, L., Hameg, A., & Llorca, P. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1121995 · Cited by 47
Role of the cholinergic system in the pathology and treatment of schizophrenia
Scarr, E., & Dean, B. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.1.73 · Cited by 45
Rowe, A. R., Mercer, L., Casetti, V., Sendt, K.-V., Giaroli, G., Shergill, S. S., & Tracy, D. K. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114564096 · Cited by 43
The use of cholecystokinin in schizophrenia: a review
Montgomery, S., & Green, M. C. D. (1988) · Psychological Medicine · doi:10.1017/s0033291700008278 · Cited by 43
Kishi, T., Mukai, T., Matsuda, Y., & Iwata, N. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8251-0 · Cited by 41
Drug development in schizophrenia: are glutamatergic targets still worth aiming at?
GOFF, D. C. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000152 · Cited by 41
Treating Impaired Cognition in Schizophrenia
Ibrahim, H. M., & Tamminga, C. A. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784772 · Cited by 40
Chaudhry, I. B., Husain, N., Drake, R., Dunn, G., Husain, M. O., Kazmi, A., Hamirani, M. M., Rahman, R., Stirling, J., & Deakin, J. F. W. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313511487 · Cited by 38
Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
Chaki, S., & Hikichi, H. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049570 · Cited by 36
The neurobiology of schizophrenia: new leads and avenues for treatment
Bray, N. J., Leweke, F. M., Kapur, S., & Meyer‐Lindenberg, A. (2010) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2010.09.008 · Cited by 32
Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
Ellenbroek, B. A., & Prinssen, E. P. M. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000102 · Cited by 31
Sasaki, T., Oga, T., Nakagaki, K., Sakai, K., Sumida, K., Hoshino, K., Miyawaki, I., Saito, K., Suto, F., & Ichinohe, N. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.01.024 · Cited by 29
Functional brain connectivity phenotypes for schizophrenia drug discovery
Dawson, N., MORRIS, B. J., & Pratt, J. A. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563635 · Cited by 29
Pushpa-Rajah, J. A., Mcloughlin, B. C., Gillies, D. M., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu168 · Cited by 28
Treating Schizophrenia: Novel Targets for the Cholinergic System
Money, T., Scarr, E., Udawela, M., Gibbons, A. S., Jeon, W. J., Seo, M. S., & Dean, B. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012062 · Cited by 26
Samadi, R., Soluti, S., Daneshmand, R., Assari, S., & Manteghi, A. A. (2017) · PubMed Central · Cited by 19
Gavin, D. P., & Floreani, C. V. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801311-3.00005-6 · Cited by 17
Pdxdc1 modulates prepulse inhibition of acoustic startle in the mouse
Feldcamp, L. A., Boutros, P. C., Raymond, R., Fletcher, P. J., Nóbrega, J. N., & Wong, A. H. C. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.85 · Cited by 15
Cited by
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
The emerging role of exosomes in mental disorders
Saeedi, S., Israel, S., Nagy, C., & Turecki, G. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0459-9 · Cited by 370
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Haddad, P. M., & Correll, C. U. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318781475 · Cited by 259
Metadata
- Authors
- Yang, A., & Tsai, S.-J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-08-03
- Volume
- 18
- Issue
- 8
- Pages
- 1689
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2740094929
- Cited by
- 282
- References
- 116
- FWCI
- 16.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.